Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNG-IUS for Preventing Endometrial Polyp Recurrence
NCT06620939Not yet recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of avatrombopag in endometrial polyp (2 arms). Primary endpoint: Endometrial polyps recurrence rate at 2 years. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
avatrombopag
03
Conditions
endometrial polyp
Beyond the preview
Go deeper on NCT06620939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06620939.